Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells $79,692.84 in Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the sale, the chief executive officer owned 130,625 shares of the company’s stock, valued at $4,541,831.25. The trade was a 1.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Berndt Modig also recently made the following trade(s):

• On Monday, June 15th, Berndt Modig sold 2,291 shares of Pharvaris stock. The shares were sold at an average price of $31.07, for a total value of $71,181.37.

Pharvaris Stock Up 0.3%

NASDAQ:PHVS opened at $36.39 on Friday. Pharvaris N.V. has a 12-month low of $20.65 and a 12-month high of $36.93. The firm has a market capitalization of $2.38 billion, a P/E ratio of -11.93 and a beta of -2.31. The stock’s fifty day simple moving average is $34.06 and its 200-day simple moving average is $30.35.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, equities research analysts expect that Pharvaris N.V. will post -3.15 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently bought and sold shares of PHVS. Quantbot Technologies LP acquired a new stake in shares of Pharvaris in the second quarter valued at approximately $41,000. GF Fund Management CO. LTD. acquired a new position in Pharvaris during the fourth quarter worth $35,000. CoreCap Advisors LLC bought a new position in Pharvaris in the second quarter valued at $93,000. Barclays PLC bought a new position in Pharvaris in the fourth quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Pharvaris in the 4th quarter valued at $86,000.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PHVS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. Citigroup restated a “market outperform” rating on shares of Pharvaris in a research report on Thursday, August 13th. UBS Group set a $74.00 price objective on Pharvaris in a research note on Wednesday, May 13th. Citizens Jmp lifted their target price on Pharvaris from $74.00 to $75.00 and gave the stock a “market outperform” rating in a report on Thursday, August 13th. Finally, Morgan Stanley boosted their target price on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a research note on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and an average target price of $51.08.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.